The National Institute on Aging welcomes all funding organizations that support research on drug discovery and preclinical drug development for Alzheimer’s and related dementias to become AlzPED partners and join NIA’s efforts to increase the reproducibility and translational value of studies testing the efficacy of candidate therapeutics in animal models.
AlzPED Partner Organizations are expected to uphold and promote best practices for transparent reporting and rigorous experimental design by:
- Disseminating best practices for study design to the scientific community.
- Incentivizing funded investigators to adhere to best practices for transparent reporting and study design by incorporating expectations for data sharing and rigorous study design as review criteria for grant applications and as terms and conditions of funding.
- Incentivizing funded investigators to use AlzPED for sharing reports from preclinical efficacy testing studies with negative findings.
- Promoting the use of best practices for transparent reporting and rigorous experimental design by providing training opportunities for students and postdoctoral fellows.
If your organization is interested in becoming an AlzPED partner, please contact us at AlzPED@nia.nih.gov.